FULCRUM THERAPEUTICS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
FULCRUM THERAPEUTICS, INC. (FULC) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $208.80 million as of 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-09-02
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $208.80M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $204.40M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $21.20M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $29.90M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $208.80M S-4 · filed 2026-09-02 |
| 2026-03-31 | $204.40M 10-Q · filed 2026-04-27 |
| 2025-12-31 | $21.20M S-4 · filed 2026-09-02 |
| 2025-09-30 | $29.90M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $75.50M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $41.80M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $40.00M 10-K · filed 2025-02-25 |
| 2024-09-30 | $8.10M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $159.00M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $125.70M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $130.20M 10-K · filed 2024-02-27 |
| 2023-09-30 | $216.60M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $222.20M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $175.20M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $111.10M 10-K/A · filed 2023-06-26 |
| 2022-09-30 | $79.70M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $128.90M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $160.30M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $180.80M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $164.20M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $48.00M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $13.10M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $13.40M 10-K/A · filed 2023-06-23 |
| 2020-06-30 | $9.00M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $21.80M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |